Sun Pharma shares hit 52-week high on acquiring Israeli company
As per the regulatory filing by the pharmaceutical major, through the acquisition, Sun Pharma aims to facilitate the consolidation of business in Israel.
pharmaceutical company
January 2024
December 2023
November 2023
October 2023
September 2023
July 2023
April 2023
Akums Drugs and Pharmaceuticals Limited: Endeavour to deliver Quality Medicines and Advancing Pharmaceutical Manufacturing
Established with a clear vision, Akums remains unwavering in its commitment to excel in the pharmaceutical industry.
Lupin shares trade 3% higher; nears 52-week high after USFDA's approval
The drug will be manufactured at Lupin’s Pithampura plant in India, says the company.
Lupin shares hit 52-week high on strong Q2 results
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
Piramal Pharma shares rise 8% after Q2 results
The company reported a consolidated net profit of ₹5 crore in the July to September quarter of FY24. The company had reported a loss of ₹37 crore in the same period last year.
Strides Pharma surges 10% on USFDA's approval for Icosapent Ethyl capsules
Strides Pharma Global Pte Limited, Singapore, which is a wholly-owned subsidiary of Strides Pharma, has received approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram, from the USFDA.
Lupin acquires five brands from Italy's Menarini to strengthen therapy portfolio
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), the company says.
Glenmark Pharma slides 6% on deal to sell drug business to Nirma
Glenmark Pharma entered into a definitive agreement with Nirma Limited to divest a 75% stake in Glenmark Life Sciences at a price of ₹615/- per share for an aggregate consideration of ₹5,615 crore.
Dr. Reddy's Q1 profit surges 18% to ₹1,403 cr
The revenue witnessed 29% growth at ₹6,738.4 crore in the Q1 of FY24, against ₹5,215.4 crore YoY, driven by sales in North America, emerging markets and Europe.
Glenmark Pharma to pay $87.5 mn to settle lawsuits in U.S.
Glenmark Pharmaceutical said that the settlement will make clear that the company denies allegations by the Plaintiff groups.
